New drug aims to tame rare nerve disease
NCT ID NCT07685678
First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time
Summary
This trial tests a drug called ripertamab in people with neuromyelitis optica spectrum disorder (NMOSD), a rare condition where the immune system attacks the optic nerves and spinal cord. Participants receive the drug by IV infusion four times over 73 weeks and are monitored for relapses and side effects. The goal is to see if ripertamab can safely reduce the number of disease attacks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ripertamab (a drug given by intravenous infusion)
- What this could lead to
- If it works, ripertamab could offer a new treatment option to reduce relapses in people with NMOSD, a rare autoimmune disease that attacks the optic nerves and spinal cord.
- What could go wrong
- This is an early-phase trial with only 20 participants, so results may not apply to everyone. The drug may cause side effects or fail to prevent relapses better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISEASE (NMOSD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.